Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 27, 2026Dermatitis

Cyclosporine and Methotrexate in Atopic Dermatitis: Bridging Therapies or Real-World Alternatives?

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCarmen García‐MorontaHospital Universitario Virgen de las NievesARAndrea Rodríguez‐SannaHospital Universitario Virgen de las NievesDMDaniel Muñoz‐BarbaHospital Universitario Virgen de las Nieves

Discussion

Loading...

Member takes

Implication

Retrospective cohort study evaluates treatment persistence and effectiveness in patients with moderate-to-severe atopic dermatitis, indicating limited benefit from conventional therapies.

Key Points

  • The study aims to assess the effectiveness, safety, and treatment persistence of cyclosporine and methotrexate in routine clinical practice for atopic dermatitis.
  • Retrospective observational cohort study in patients with moderate-to-severe atopic dermatitis.
  • Patients initiated cyclosporine or methotrexate as first-line systemic therapy.
  • Clinical improvement was measured using the Eczema Area and Severity Index and itch scales upon treatment initiation and discontinuation.
  • 113 patients were included with a mean age of 33.7 years.
  • Conventional therapy showed modest improvement (EASI change −0.66, P=0.439) but significant reduction in pruritus (NRS itch change −1.3, P=0.001).
  • 96% of patients discontinued treatment mainly due to lack of efficacy (68.8%); 76% escalated to advanced therapies, resulting in substantial improvements in EASI (−11.1, P<0.001) and NRS itch (−3.2, P<0.001).

Cite This Study

García‐Moronta et al. (2026) studied this question.

synapsesocial.com/papers/6a168a340c924ddd1bd58dfbhttps://doi.org/10.1177/17103568261452370
View Full Paper
Ask AI
Bookmark
Share